Invitrogen and BMG LABTECH in resource share alliance

A selection of Invitrogen's drug discovery products is to be tested on BMG LABTECH's microplate detection instrumentation as part of a new collaboration between the two companies.

And BMG LABTECH instruments, such as the PHERAstar and OMEGA series, will be certified for use with specific Invitrogen technology platforms.

Initial certifications will focus on Invitrogen's assay systems for key target classes, such as LanthaScreen TR-FRET for protein kinases, PolarScreen FP technology for nuclear receptors, GeneBLAzer reporter-gene technology for G protein-coupled receptors and Adapta, a new TR-FRET assay system for lipid kinases. This collaboration will allow BMG LABTECH and Invitrogen, a Californian-based life science technology provider for research, production and diagnostics areas, to develop and promote joint applications for the drug discovery market.

"Through this partnership, researchers will be able to obtain integrated instrumentation and reagent solutions, thereby removing the frustration of discovering that the biological assay system they have chosen is not compatible with the instrumentation and visa versa," said John Printen, director of Invitrogen's Cell Signaling business segment. "This is critical for reaching customers across pharmaceutical research, biotech, academics and government where those scientists are seeking a higher throughput solution for their discovery workflows."

"BMG LABTECH has a strong installed customer base in both the pharmaceutical sector and the academic research market. Our customers in both market segments demand high performance instrumentation and assay systems," said Dr Ronald Earp, president of BMG LABTECH. This partnership will ensure that their BMG LABTECH microplate readers will provide optimal performance on Invitrogen assay technologies and allow us to proactively develop instrumentation for future platforms."